Real-world Healthcare Resource Utilization Following Initiation of Subcutaneous IgPro20 Among U.S. Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Batyrkhan Kuatov1, Shicheng Weng1, Laurence Undreiner1, Aisara Chansakul2, Elizabeth Dabrowski2, Ann Madsen2
1CSL Behring, 2Aetion, Inc.
Objective:
Characterize HCRU among CIDP patients who initiate subcutaneous IgPro20 (Immune Globulin [Human], 20% Liquid).
Background:
Intravenous immunoglobulin (IVIg) therapy, during the maintenance phase of chronic inflammatory demyelinating polyneuropathy (CIDP) management, requires infusions in a health care setting. Subcutaneous immunoglobulins (SCIg) can be self-administered at home, increasing patient autonomy. However, the impact of IgPro20 initiation on healthcare resource utilization (HCRU) has not been characterized in a US real-world setting.
Design/Methods:
This retrospective cohort study used Optum’s de-identified Clinformatics® Data Mart Database (study period: 01/2014 - 12/2024). Adult patients with ≥ 2 CIDP diagnosis claims and ≥ 6 months of enrollment pre and post index entered the cohort upon IgPro20 initiation (index date). Rates per person per year (PPPY) of inpatient (IP), emergency department (ED), and outpatient (OP) claims were evaluated in the 6-month pre-index and 6-month post-index periods.
Results:
CIDP patients meeting eligibility criteria (n=207) were 60 years old (median) and male (54%). Following IgPro20 initiation, all-cause IP claims decreased from 0.52 PPPY (SD 1.43) to 0.42 PPPY (SD 1.60); ED claims decreased from 1.00 (SD 2.15) to 0.85 PPPY (SD 2.44).
Post IgPro20 initiation, all-cause OP claims increased from 60.62 (SD 41.62) to 78.33 (SD 41.98) PPPY, largely attributable to IgPro20-related claims and administrative services, especially nursing/home care visits for self-administration training during the first month. Thereafter, all-cause OP claims PPPY decreased from month 1 to month 6 post-index, eventually reaching 67.43 (SD 44.70) PPPY during the 6th month. All other OP HCRU metrics (e.g, OP claims unrelated to IgPro20/training) decreased post-index.
Conclusions:
IgPro20 demonstrated a favorable profile in the management of CIDP, with care shifting away from IP and ED settings toward OP. After self-administration training in month one, findings highlight reduced healthcare burden over a longer horizon.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.